Inhibitors of the tumor necrosis factor receptor complex

Patent metadata

Field	Value
Publication number	US-9751830-B2
Application number	US-201113634368-A
Country	US
Kind code	B2
Filing date	Mar 7, 2011
Priority date	Mar 15, 2010
Publication date	Sep 5, 2017
Grant date	Sep 5, 2017

Abstract

The present invention relates to compounds of formula (I) that are inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions: Formula (I)

First claim

What is claimed:

1. A compound having the structure of formula I:

wherein,
A 1 -A 5 and B 1 -B 4 are independently H, halo, hydroxyl, nitro, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted acyl, —(CH 2 ) m —S(O) q R 2 , —N(R 1 ) 2 , —(CH 2 ) m —X 4 —C(X 5 )—R 2 , —(CH 2 ) m —C(X 5 )—X 4 —R 2 , —O—(CH 2 ) m —X 4 —C(X 5 )—R 2 , —O—(CH 2 ) m —C(X 5 )—X 4 —R 2 , —SO 3 H, or —S(O) q —R 1 , or one or more pairs of A 1 -A 2 or A 2 -A 3 or A 3 -A 4 , or A 4 -A 5 or B 1 -B 2 or B 3 -B 4 , together with the respective carbons to which they are attached, form a C 4-8 alkyl, heteroalkyl, aryl, or heteroaryl ring, provided that at least one of A 1 -A 5 moieties comprises—(CH 2 ) m —X 4 —C(X 5 )—R 2 ;
X 1 , X 2 , and X 5 are O;
X 4 is independently O or NH;
X 3 is NR 1 ;
m, n, and p and are each independently 0 or 1; q is 0, 1, or 2;
R 1 is independently in each case H, or optionally substituted aryl, heteroaryl, alkyl, or acyl;
R 2 is optionally substituted alkyl, aryl, or heteroaryl;
R 3 is independently in each case H, R 1 , —OR 1 , or when taken together with another R 3 attached to the same carbon is ═O;
and provided that the compound does not have the structure of formula II:

2. The compound of claim 1 wherein said compound is capable of binding in a cavity of a tumor necrosis factor receptor (TNF-R), said cavity bounded by Cys-76, Arg-77, Asp-93, Cys-96, Arg-104, Asn-110, Phe-112, and Lys-132 of SEQ ID No. 0001.

3. The compound of claim 1 wherein A 5 is —(CH 2 ) m —X 4 —C(X 5 )—R 2 .

4. The compound of claim 1 wherein X 3 is NH.

5. The compound of claim 3 wherein A 1 , A 2 , A 3 , and A 4 are H.

6. The compound of claim 1 wherein A 4 is —(CH 2 ) m —X 4 —C(X 5 )—R 2 and wherein A 1 , A 2 , A 3 , and A 5 are H.

7. The compound of claim 1 wherein A 3 is —(CH 2 ) m —X 4 —C(X 5 )—R 2 and wherein A 1 , A 2 , A 4 , and A 5 are H.

8. The compound of claim 4 wherein m=0 or 1, X 5 is O, and R 2 is C 1-3 linear alkyl.

9. The compound of claim 8 wherein —(CH 2 ) m —X 4 —C(O)—R 2 is —(CH 2 )—X 4 —C(O)CH 3 .

10. The compound of claim 8 wherein —(CH 2 ) m —X 4 —C(O)—R 2 is —X 4 —C(O)CH 3 .

11. The compound of claim 1 wherein n=0.

12. The compound of claim 3 wherein n=0.

13. The compound of claim 1 wherein p=0.

14. The compound of claim 3 wherein p=0.

15. The compound of claim 1 or 3 , wherein n=p=0.

16. The compound of claim 1 wherein R 1 is linear or branched C 1-3 alkyl or branched C 1-3 carboxyalkyl and R 2 is linear or branched C 1-3 alkyl or linear.

17. The compound of claim 16 wherein R 1 and R 2 are each independently fluorinated or perfluorinated.

18. The compound of claim 1 having the structure:

wherein R 1 is each independently H, linear or branched C 1-3 alkyl, or linear or branched C 1-3 carboxyalkyl and R 2 is linear or branched C 1-3 alkyl.

19. The compound of claim 18 having the structure:

20. The compound of claim 18 having the structure:

21. The compound of claim 18 having the structure:

22. The compound of claim 18 having the structure:

23. A compound of claim 1 that inhibits at least 40% of TNFα induced cytolysis at a concentration of 50 micromolar.

24. A compound of claim 1 that inhibits at least 60% of TNFα induced cytolysis at a concentration of 90 micromolar.

25. A compound of claim 1 that inhibits at least 40% of luciferase activity within 4 hours of incubation with 20 ng/ml TNFα for 4 hours, at a concentration of 75 micromolar of the compound.

26. A compound of claim 1 that inhibits at least 60% of luciferase activity within 4 hours of incubation with 20 ng/ml TNFα for 4 hours, at a concentration of 100 micromolar of the compound.

27. A pharmaceutical composition comprising a compound according to claim 1 or a compound having the structure of formula II

and a pharmaceutically acceptable excipient.

28. A pharmaceutical composition of claim 27 , wherein said compound is present in an amount effective to inhibit the activity of a tumor necrosis factor alpha (TNF-α) protein.

29. A method of treating a patient having an inflammatory disease condition mediated by tumor necrosis factor alpha (TNFα) activity, the method comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1 or a compound having the structure of formula II

or a pharmaceutically acceptable salt thereof.

30. The method of claim 29 wherein the compound causes an allosteric change in the conformation of TNF-R.

31. The method of claim 29 , wherein the inflammatory disease condition is arthritis.

32. The method of claim 29 , wherein the inflammatory disease condition is Crohn's Disease.

33. The method of claim 29 , wherein the inflammatory disease condition is inflammatory neuropathy, Lou Gehrig's disease, or Alzheimer's disease.

34. The pharmaceutical composition of claim 27 , comprising a compound having the structure of formula II

and a pharmaceutically acceptable excipient.

35. The pharmaceutical composition of claim 27 , wherein the compound of claim 1 is:

wherein R 1 is each independently H, linear or branched C 1-3 alkyl, or linear or branched C 1-3 carboxyalkyl and R 2 is linear or branched C 1-3 alkyl.

36. The pharmaceutical composition of claim 27 , wherein the compound of claim 1 is:

37. The method of claim 29 , wherein the compound has the structure of formula II

38. The method of claim 29 , wherein the compound of claim 1 is

wherein

Assignees

• Murali Ramachandran
• Greene Mark I
• Univ Pennsylvania

Inventors

• Murali Ramachandran
• Greene Mark I

Classifications

• C07C233/25 Primary

  having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton · CPC title

• C07C217/20

  by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms · CPC title

• C07C217/32

  the six-membered aromatic ring or condensed ring system containing that ring being further substituted · CPC title

• C07C217/18

  the six-membered aromatic ring or condensed ring system containing that ring being further substituted · CPC title

• C07C233/18

  having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton · CPC title